Autolus Therapeutics (NASDAQ:AUTL) Sees Strong Trading Volume – Should You Buy?

by · The Cerbat Gem

Shares of Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) saw strong trading volume on Thursday . 5,096,923 shares traded hands during mid-day trading, an increase of 278% from the previous session’s volume of 1,349,308 shares.The stock last traded at $3.58 and had previously closed at $4.00.

Autolus Therapeutics Stock Down 16.5 %

The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The company has a market cap of $888.75 million, a P/E ratio of -2.94 and a beta of 2.04. The business’s 50 day moving average is $4.04 and its 200 day moving average is $4.07.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. ProShare Advisors LLC purchased a new stake in Autolus Therapeutics in the second quarter valued at about $43,000. Daiwa Securities Group Inc. boosted its stake in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new stake in Autolus Therapeutics during the 3rd quarter worth approximately $91,000. Bayesian Capital Management LP acquired a new position in Autolus Therapeutics during the 1st quarter valued at approximately $100,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Autolus Therapeutics in the first quarter worth $108,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

(Get Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Read More